Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: fezakinumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 6,060 | 0.71 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5559
Sealed predictions
- IL22 in dopamine neurons, braak+0.33 (p 0.387) → +0.14 (p 0.714)receipt 5567
Swarm cases
receipt 5567: IL22 in dopamine neurons, braak
- power
- full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.429, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range +0.06 to +0.32, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL22 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts